{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:03:16Z","timestamp":1791388996633,"version":"4.3.3"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.coph.2018.08.008","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T12:11:51Z","timestamp":1535976711000},"page":"53-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Opioid receptors in the GI tract: targets for treatment of both diarrhea and constipation in functional bowel disorders?"],"prefix":"10.1016","volume":"43","author":[{"given":"J","family":"Pannemans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Corsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2018.08.008_bib0005","article-title":"Bowel disorders","author":"Mearin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2018.08.008_bib0010","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2018.08.008_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2018.08.008_bib0020","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.pain.2004.09.019","article-title":"Opioids in chronic non-cancer pain: systematic review of efficacy and safety","volume":"112","author":"Kalso","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.coph.2018.08.008_bib0025","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1053\/gast.2000.16484","article-title":"The impact of irritable bowel syndrome on health-related quality of life","volume":"119","author":"Gralnek","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2018.08.008_bib0030","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/ajg.2014.187","article-title":"American college of gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2018.08.008_bib0035","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1358\/dot.2015.51.8.2364896","article-title":"Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation","volume":"51","author":"Corsetti","year":"2015","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.coph.2018.08.008_bib0040","doi-asserted-by":"crossref","first-page":"11s","DOI":"10.1016\/S0002-9610(01)00782-6","article-title":"Incidence, prevalence, and management of opioid bowel dysfunction","volume":"182","author":"Pappagallo","year":"2001","journal-title":"Am J Surg"},{"key":"10.1016\/j.coph.2018.08.008_bib0045","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1517\/14656566.2015.991306","article-title":"Naloxegol, a new drug for the treatment of opioid-induced constipation","volume":"16","author":"Corsetti","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl. 2","key":"10.1016\/j.coph.2018.08.008_bib0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1743-3150.2004.00553.x","article-title":"The opioid system in the gastrointestinal tract","volume":"16","author":"Sternini","year":"2004","journal-title":"Neurogastroenterol Motil"},{"issue":"Suppl. 2","key":"10.1016\/j.coph.2018.08.008_bib0055","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1743-3150.2004.00555.x","article-title":"Preclinical studies of opioids and opioid antagonists on gastrointestinal function","volume":"16","author":"Greenwood-Van Meerveld","year":"2004","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.coph.2018.08.008_bib0060","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.2165\/11634970-000000000-00000","article-title":"Opioid-induced bowel dysfunction: pathophysiology and management","volume":"72","author":"Brock","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2018.08.008_bib0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.regpep.2009.03.012","article-title":"Opioid receptors in the gastrointestinal tract","volume":"155","author":"Holzer","year":"2009","journal-title":"Regul Pept"},{"key":"10.1016\/j.coph.2018.08.008_bib0070","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0301-0082(01)00023-5","article-title":"Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and \u03b2-arrestin proteins","volume":"66","author":"Claing","year":"2002","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.coph.2018.08.008_bib0075","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/0016-5085(88)90673-7","article-title":"Role of opiate receptors in the regulation of colonic transit","volume":"94","author":"Kaufman","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2018.08.008_bib0080","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/13543784.16.2.181","article-title":"Treatment of opioid-induced gut dysfunction","volume":"16","author":"Holzer","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.coph.2018.08.008_bib0085","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/1097-0185(20010101)262:1<58::AID-AR1011>3.0.CO;2-V","article-title":"Classes of enteric nerve cells in the guinea\u2010pig small intestine","volume":"262","author":"Brookes","year":"2001","journal-title":"Anatom Rec"},{"key":"10.1016\/j.coph.2018.08.008_bib0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ajgsup.2014.5","article-title":"Molecular physiology of enteric opioid receptors","volume":"2","author":"Galligan","year":"2014","journal-title":"Am J Gastroenterol Suppl (Print)"},{"issue":"Suppl. 2","key":"10.1016\/j.coph.2018.08.008_bib0095","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1743-3150.2004.00554.x","article-title":"Function of opioids in the enteric nervous system","volume":"16","author":"Wood","year":"2004","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.coph.2018.08.008_bib0100","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0016-5085(84)80161-4","article-title":"Mechanism of the antidiarrheal effect of loperamide","volume":"86","author":"Schiller","year":"1984","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2018.08.008_bib0105","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1440-1681.2007.04649.x","article-title":"Cerebral uptake of drugs in humans","volume":"34","author":"Upton","year":"2007","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.coph.2018.08.008_bib0110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/00365528709091003","article-title":"Loperamide in treatment of irritable bowel syndrome\u2009\u2014\u2009a double-blind placebo controlled study","volume":"130","author":"Lavo","year":"1987","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.coph.2018.08.008_bib0115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/00365528709091004","article-title":"Loperamide treatment of the irritable bowel syndrome","volume":"130","author":"Hovdenak","year":"1987","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.coph.2018.08.008_bib0120","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/00365529609006766","article-title":"A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome","volume":"31","author":"Efskind","year":"1996","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.coph.2018.08.008_bib0125","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF01296258","article-title":"Role of loperamide and placebo in management of irritable bowel syndrome (IBS)","volume":"29","author":"Cann","year":"1984","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.coph.2018.08.008_bib0130","series-title":"U.S. Food & Drug Administration","year":"2018"},{"key":"10.1016\/j.coph.2018.08.008_bib0135","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s40265-015-0436-4","article-title":"Eluxadoline: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2018.08.008_bib0140","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.04.006","article-title":"Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study","volume":"145","author":"Dove","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2018.08.008_bib0145","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1016\/j.bmcl.2012.05.042","article-title":"Identification of a dual delta OR antagonist\/mu OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d)","volume":"22","author":"Breslin","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.coph.2018.08.008_bib0150","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.08.008_bib0155","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/ajg.2017.72","article-title":"Eluxadoline efficacy in IBS-D patients who report prior loperamide use","volume":"112","author":"Lacy","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2018.08.008_bib0160","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/apt.14504","article-title":"Postmarketing cases of eluxadoline-associated pancreatitis in patients with or without a gallbladder","volume":"47","author":"Harinstein","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2018.08.008_bib0165","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/ajg.2017.257","article-title":"Safety of eluxadoline in patients with IBS-D without a gallbladder","volume":"112","author":"Cash","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2018.08.008_bib0170","unstructured":"Positive results for NKTR-118 (oral PEG-naloxol) presented at american academy of pain management meeting. (2007, Sep 26). PR Newswire Retrieved from: https:\/\/search-proquest-com.kuleuven.ezproxy.kuleuven.be\/docview\/450919208?accountid=17215 (05.08.18)."},{"key":"10.1016\/j.coph.2018.08.008_bib0175","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1310246","article-title":"Naloxegol for opioid-induced constipation in patients with noncancer pain","volume":"370","author":"Chey","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.08.008_bib0180","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/2050640615604543","article-title":"Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response","volume":"3","author":"Tack","year":"2015","journal-title":"Unit Eur Gastroenterol J"},{"key":"10.1016\/j.coph.2018.08.008_bib0185","doi-asserted-by":"crossref","first-page":"405","DOI":"10.5055\/jom.2016.0360","article-title":"A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation","volume":"12","author":"Webster","year":"2016","journal-title":"J Opioid Manage"},{"key":"10.1016\/j.coph.2018.08.008_bib0190","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/1074248418760239","article-title":"Cardiovascular safety of the selective mu-opioid receptor antagonist naloxegol: a novel therapy for opioid-induced constipation","volume":"23","author":"White","year":"2018","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.coph.2018.08.008_bib0195","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0028-3908(85)90072-3","article-title":"The use of quaternary narcotic antagonists in opiate research","volume":"24","author":"Brown","year":"1985","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.coph.2018.08.008_bib0200","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0009-9236(96)90117-4","article-title":"Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial","volume":"59","author":"Yuan","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.coph.2018.08.008_bib0205","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1067\/mcp.2000.105037","article-title":"Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time","volume":"67","author":"Yuan","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.coph.2018.08.008_bib0210","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0009-9236(97)90197-1","article-title":"The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time","volume":"61","author":"Yuan","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.coph.2018.08.008_bib0215","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/j.1365-2036.2010.04422.x","article-title":"The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health","volume":"32","author":"Wong","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2018.08.008_bib0220","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jpain.2010.11.008","article-title":"Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study","volume":"12","author":"Michna","year":"2011","journal-title":"J Pain"},{"key":"10.1016\/j.coph.2018.08.008_bib0225","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jpainsymman.2010.01.011","article-title":"Methylnaltrexone and gastrointestinal perforation","volume":"40","author":"Mackey","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.coph.2018.08.008_bib0230","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/papr.12535","article-title":"Randomized, double-blind trial of oral methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic noncancer pain","volume":"17","author":"Rauck","year":"2017","journal-title":"Pain Pract"},{"key":"10.1016\/j.coph.2018.08.008_bib0235","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/pm\/pnw325","article-title":"A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain","volume":"18","author":"Webster","year":"2017","journal-title":"Pain Med"},{"key":"10.1016\/j.coph.2018.08.008_bib0240","unstructured":"SYMPROIC\u00ae (naldemedine) tablets, for oral use, C-II, Initial U.S. Approval: 2017. HIGHLIGHTS OF PRESCRIBING INFORMATION. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208854slbl.pdf (accessed 05.07.18)."},{"key":"10.1016\/j.coph.2018.08.008_bib0245","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S2468-1253(17)30105-X","article-title":"Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials","volume":"2","author":"Hale","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2018.08.008_bib0250","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/j.pain.0000000000001174","article-title":"Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study","volume":"159","author":"Webster","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.coph.2018.08.008_bib0255","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpain.2010.06.013","article-title":"A randomized, placebo-controlled phase 3 trial (Study SB-767905\/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain","volume":"12","author":"Irving","year":"2011","journal-title":"J Pain"},{"key":"10.1016\/j.coph.2018.08.008_bib0260","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jpain.2010.06.012","article-title":"A randomized, placebo-controlled phase 3 trial (Study SB-767905\/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain","volume":"12","author":"Jansen","year":"2011","journal-title":"J Pain"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218300146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218300146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:50:36Z","timestamp":1761461436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489218300146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":52,"alternative-id":["S1471489218300146"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2018.08.008","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opioid receptors in the GI tract: targets for treatment of both diarrhea and constipation in functional bowel disorders?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2018.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}